J&J expects to file for approval of 11 drugs by 2015

05/26/2011 | Wall Street Journal, The · Reuters

Johnson & Johnson intends to submit 11 treatments for regulatory approval by 2015, the health care giant told analysts and investors. Among them are Alzheimer's disease medicine bapineuzumab and type 2 diabetes drug canagliflozin. "We are returning to growth, and we expect to outpace market growth," said Sheri McCoy, vice chairwoman and executive-committee member.

View Full Article in:

Wall Street Journal, The · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR